MedPath

A study to evaluate the effectiveness of a community based intense lifestyle intervention program to facilitate the conversion of dysglycemia (abnormal glucose level) to normoglycemia (normal glucose level)

Completed
Conditions
Prediabetes
Registration Number
CTRI/2021/07/035289
Lead Sponsor
Wellcome Trust DBT India Alliance
Brief Summary

India has the second-largest number of people (77 million) living with T2DM, next only to China, with at least as many more undiagnosed. Kerala, the southernmost State of India is the most advanced state in epidemiological transition with the highest prevalence of T2DM (nearly 20 %) and its risk factors in the country. High prevalence rates of overweight (nearly half) and physical inactivity among women in Kerala pose a continuing threat to the T2DM burden. Most landmark lifestyle modification trials were done on individuals with impaired glucose tolerance (IGT)   as it is a better predictor of micro-vascular complications and metabolic syndrome and is a strong predictor of cardiovascular complications. However, the annual risk to the progression of T2DM is over 5 times for individuals with isolated impaired glucose tolerance (iIGT), 7 times for isolated impaired fasting glucose (iIFG) and over 12 times for those with both IFG and IGT when compared to normoglycemic individuals. Till date, only three large trials, one in Japan and two in India were conducted to prevent T2DM among individuals with iIFG. However, all the three trials targeted individuals across pre-diabetes spectrum and found lower risk reduction among the iIFG group when compared to iIGT and IGT+IFG group. Lack of evidence on positive effects of lifestyle modification in the iIFG group among Asian Indians warrant further exploration on strategies to reduce the incidence of T2DM as individuals with isolated impaired fasting glucose constitute a major group (57.5%)  in the pre-diabetes spectrum among Indians. Furthermore, it is vital to see the effect of intense lifestyle modification intervention across the IFG spectrum in a representative sample of individuals with IFG. Early regression to normoglcemia in people with impaired glucose regulation is associated with reduction in T2DM and no trials have shown such effects in those with i-IFG.

This study aims to assess the effectiveness of a community based intense lifestyle modification program among women with isolated impaired fasting glucose in regression from dysglycemic state (iIFG) to normoglycemia. Collectivistic family centered decision making over individualistic in Kerala emphasizes the importance of peer support, family involvement and community engagement for a sustained behaviour change.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
448
Inclusion Criteria

(I) Inclusion criteria for screening (stage 1): 1)Women aged 30-60 years, 2) able to read, write and speak Malayalam, the local language 3) consents to participate in the study, 4) not a known diabetic, 5) no prior history of GDM (II) Inclusion criteria for the trial (stage 4): Participants should satisfy all the inclusion criteria for screening and should be diagnosed with isolated impaired fasting glucose in OGTT.

Exclusion Criteria
  • (i)Exclusion criteria for screening: -Women with T2DM, diabetes in pregnancy -With prior history of GDM, having chronic illnesses/ disease conditions or on medications that alter glucose metabolism will be excluded.
  • Women with mental illness based on ICD-10 classification44 will also be excluded (ii) Exclusion criteria for the trial: all exclusion criteria for screening and also the newly diagnosed with diabetes or diabetes in pregnancy will be excluded.
  • A screening questionnaire will be used to ensure that participants meet the inclusion and exclusion criteria.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of regression from iIFG to normoglycemia at 24 monthsIncidence of regression from iIFG to normoglycemia at 24 months
Secondary Outcome Measures
NameTimeMethod
1. Glycemic level assessment2. Lipid profile assessment

Trial Locations

Locations (1)

Central University of Kerala

🇮🇳

Kasaragod, KERALA, India

Central University of Kerala
🇮🇳Kasaragod, KERALA, India
Dr Elezebeth Mathews
Principal investigator
9495221707
elezebethmathews@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.